T2 Project AD Study Tests Biohaven’s Investigational Drug Troriluzole for Alzheimer’s Disease

Feb 21, 2019 | Alzheimer's Disease Trial, CNS

The T2 Protect AD clinical study test Biohaven’s new investigational drug called troriluzole, seeking to assess if the neuroprotectant can protect against, slow down or stop memory and thinking problems in people between ages 50 and 85 already diagnosed with mild-to moderate Alzheimer’s.   

What Research Sites are Participating?

The link to the map provides a list of participating sites.


Pin It on Pinterest